83435-58-9

Basic information

• Product Name: Boc-D-prolinol
• Synonyms: BOC-D-PRO-OL;BOC-D-PROLINOL;BOC-(R)-2-(HYDROXYMETHYL) PYRROLIDINE;N-TERT-BUTOXYCARBONYL-D-PROLINOL;N-T-BUTOXYCARBONYL-D-PROLINOL;N-T-BOC-D-PROLINOL;N-BOC-D-PROLINOL;N-ALPHA-T-BOC-D-PROLINOL
• CAS NO: 83435-58-9
• Molecular Formula: C₁₀H₁₉NO₃
• Molecular Weight: 201.26
• EINECS: 1592732-453-0
• Product Categories: Alcohol Aldehyde & acid series;Amino Acids;Chiral Building Blocks;Glycidyl Compounds, etc. (Chiral);Synthetic Organic Chemistry;Chiral Products
• Mol File: 83435-58-9.mol
• Article Data: 51

Chemical Properties

• Melting Point: 60-64 °C(lit.)
• Boiling Point: 289.5 °C at 760 mmHg
• Flash Point: 128.9 °C
• Appearance: White to light beige/Crystalline Powder
• Density: 1.084 g/cm₃
• Refractive Index: 54 ° (C=5, MeOH)
• Storage Temp.: Store at 0°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 14.77±0.10(Predicted)
• Water Solubility: insoluble
• CAS DataBase Reference: Boc-D-prolinol(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-D-prolinol(83435-58-9)
• EPA Substance Registry System: Boc-D-prolinol(83435-58-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-20/21/22
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 83435-58-9(Hazardous Substances Data)

Usage

Description

Boc-D-prolinol, also known as N-(tert-Butoxycarbonyl)-D-prolinol, is a chiral compound derived from the amino acid proline. It possesses a unique structure with a tert-butoxycarbonyl (Boc) protecting group, which makes it a versatile building block in organic synthesis. Its chiral center allows for the creation of enantiomerically pure compounds, which are essential in the development of pharmaceuticals and agrochemicals.

Uses

Used in Pharmaceutical Industry:
Boc-D-prolinol is used as a chiral building block for the synthesis of enantiomerically pure compounds with therapeutic potential. Its unique structure allows for the development of novel drugs with improved efficacy and selectivity.
Used in Central Nervous System (CNS) Disorders Treatment:
Boc-D-prolinol is used as a key intermediate in the preparation of (azetidinyl)methoxy]pyridines and 2-(aryloxymethyl) azacyclic analogs. These compounds have shown therapeutic potential for the treatment of central nervous system disorders, offering new avenues for the development of effective treatments.

Upstream product

• 37784-17-1 N-(tert-butoxycarbonyl)-D-proline 
• 68832-13-3 D-prolinol 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 24424-99-5 di-tert-butyl dicarbonate 
• 73323-65-6 1-(tert-butyl) 2-methyl (R)-pyrrolidine-1,2-dicarboxylate 
• 145681-01-2 (+/-)-N-tert-butoxycarbonylproline methyl ester 
• 15761-39-4 N-tert-butoxycarbonyl-proline 
• 101555-60-6 2-(R)-carboxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1315053-73-6 C₅H₁₁NO 
• 1301760-11-1 C₁₅H₂₅NO₅ 
• 344-25-2 D-Prolin 
• 147-85-3 L-proline 
• 43041-12-9 methyl (2R)-pyrrolidine-2-carboxylate 

Downstream Products

• 73365-02-3 tert-butoxycarbonyl-D-prolinal 
• 128510-88-3 tert-butyl (R)-2-(4-methylbenzenesulfonyloxymethyl)pyrrolidine-1-carboxylate 
• 215918-30-2 tert-butyl (2R)-2-(benzyloxymethyl)pyrrolidine-1-carboxylate 
• 578741-10-3 (R)-N-tert-butoxycarbonyl-2-methoxymethylpyrrolidine 
• 210963-90-9 1-t-butoxycarbonyl-(2R)-2-chloromethylpyrrolidine 
• 59378-82-4 N-(tert-butoxycarbonyl)pyrrolidine-2-carboxaldehyde 
• 955359-78-1 1,1-dimethylethyl (2R)-2-{[4-[(4-chlorophenyl)methyl]-1-oxo-2(1H)-phthalazinyl]methyl}-1-pyrrolidinecarboxylate 
• 955359-82-7 1,1-dimethylethyl (2R)-2-{[4-(4-methoxyphenylmethyl)-1-oxo-2(1H)-phthalazinyl]methyl}pyrrolidine-1-carboxylate 
• 1141946-37-3 C₂₄H₂₇ClN₄O₃ 
• 1016641-60-3 C₂₆H₂₆N₄O₆ 
• 769961-18-4 (R)-2-(5-nitro-2-trifluoromethyl-phenoxymethyl)-1-(tert-butylcarbonyl)pyrrolidine 
• 952490-83-4 (R)-2-(5-nitro-2-pentafluoroethyl-phenoxymethyl)-1-(tert-butylcarbonyl)pyrrolidine 
• 952490-85-6 (R)-2-((5-nitro-2-(trifluoromethyl)phenoxy)methyl)-pyrrolidine 
• 952490-88-9 (R)-1-methyl-2-((5-nitro-2-(trifluoromethyl)phenoxy)methyl)-pyrrolidine 

Relevant articles and documents

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

Pyrrolidine-Oxadiazolone Conjugates as Organocatalysts in Asymmetric Michael Reaction

Pyrrolidine-oxadiazolone based organocatalysts are envisaged, synthesized, and utilized for asymmetric Michael reactions. Results of the investigations suggest that some of the catalysts are indeed efficient for stereoselective 1,4-conjugated Michael additions (dr: >97:3, ee up to 99%) in high chemical yields (up to 97%) often in short reaction time. As an extension, one enantiopure Michael adduct has been utilized to synthesize optically active octahydroindole.

FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME

Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.